Thu Mar 6, 2025 07:00 am
Sharps Technology's CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, As we reflect on the progress since our December update, I am excited to share the latest developments that will shape our Company’s trajectory in 2025 and beyond. With the successful closing of a $20 million financing in January, we strengthened our balance sheet by securing working capital for operating and capital expenditures and paid down our debt to zero. We believe that we are now well-positioned to a...
Wed Jan 29, 2025 10:45 am
Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering ...
Tue Jan 28, 2025 09:00 am
Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offe...
Thu Dec 5, 2024 10:00 am
Sharps Technology's CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue
Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery schedule Initial production and commercial deliveries to begin in Q1 2025 Sales team has signed an agreement to sell and deliver current SecureGard 1mL and 3mL inventory, with shipments and revenue that began in early December NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Techno...
Thu Dec 5, 2024 08:30 am
Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early December Agreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025 The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024 NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” ...